Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae
(Thomson Reuters ONE) -
illumigene® Mycoplasma Direct provides fast and accurate results in less than 1
hour for immediate and targeted treatment
CINCINNATI, April 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc.
(NASDAQ:VIVO) today announced that it has received the CE Mark for a new
molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae). The new and
improved illumigene Mycoplasma Direct assay features a simplified procedure
compared to the existing illumigeneMycoplasma product. The new procedure will
significantly expand Meridian's customer base by eliminating the need for
specialized techniques and training, as well as providing definitive results in
less than one hour.
The launch of illumigene Mycoplasma Direct adds to the already
robust illumigene menu that includes molecular tests for Group
A Streptococcus, Pertussis, C. difficile, Chlamydia, Gonorrhea, HSV 1&2, Group
B Streptococcus, and Malaria. All illumigene products are distributed in the
EMEA regions by Meridian Bioscience Europe and in additional international
markets by the Company's global distribution network.
Mike Shaughnessy, Executive Vice President and President of Meridian Global
Diagnostics stated, "We are excited to improve upon the only CE-marked and FDA-
cleared stand-alone molecular assay for Mycoplasma
pneumoniae (illumigene Mycoplasma). By simplifying the procedure we are able to
provide more customers with a superior diagnostic tool that will improve patient
care. Due to the lack of cell wall in Mycoplasma, typical antibiotics like
penicillin and cephalosporin are not effective, making rapid, targeted detection
for appropriate treatment of the utmost importance."
Often referred to as "walking pneumonia", M. pneumoniae is associated with up to
40% of community-acquired pneumonias and has been increasingly prevalent in the
majority of data-reporting European countries. Infection occurs in both children
and adults without geographical, gender or climate-related restrictions. M.
pneumoniae is most often associated with atypical pneumonia, presenting with
symptoms that include headache, malaise, fever and sore throat accompanied by
dry, paroxysmal cough.
illumigene Mycoplasma Direct is effective immediately as symptoms appear, by
amplifying the specific DNA for the detection of active Mycoplasma
pneumoniae infection. This represents a significant advancement in improving
healthcare diagnoses and outcomes by providing a fast and definitive result,
thus helping to ensure that patients receive the appropriate antibiotic therapy
in a timely manner. M. pneumoniae bacterial culture lacks sensitivity and is
often impractical for patient management as the organism may take as long as up
to six weeks to culture. The ability to avoid treating patients empirically will
reduce the administration of broad spectrum antibiotics and the likelihood of
antimicrobial resistance.
The illumigene Mycoplasma test utilizes throat swabs and provides highly
sensitive and specific results. It requires no expensive capital equipment or
service contract. The test relies upon a simple procedure that takes less than
two minutes of hands on time. The simplicity of this technology, along with its
cost efficiency and small footprint, makes this innovative test ideal for
enabling a more rapid diagnosis; providing earlier identification of outbreaks
and prevention of secondary cases though implementation of control measures.
About Meridian Bioscience, Inc
Meridian is a fully integrated life science company that develops markets and
distributes a broad range of innovative diagnostic tests, purified reagents and
related products and offers biopharmaceutical enabling technologies in more than
60 countries worldwide. Utilizing a variety of methods, these products and
diagnostic tests provide accuracy, simplicity and speed in the early diagnosis
and treatment of common medical conditions, such as gastrointestinal, viral and
respiratory infections. Meridian's diagnostic products are used outside of the
human body and require little or no special equipment. The Company's products
are designed to enhance patient well-being while reducing the total outcome
costs of health care. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology, parasitology and
fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents,
specialty biologicals and related technologies used by biopharmaceutical
companies engaged in research for new drugs and vaccines. For more information
please visit www.meridianbioscience.com.
Contact: 513.271.3700
John A. Kraeutler, Chief Executive Officer
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Meridian Bioscience, Inc. via GlobeNewswire
[HUG#2007652]
Unternehmensinformation / Kurzprofil:
Datum: 28.04.2016 - 08:00 Uhr
Sprache: Deutsch
News-ID 467114
Anzahl Zeichen: 5697
contact information:
Town:
Cincinnati
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 227 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae"
steht unter der journalistisch-redaktionellen Verantwortung von
Meridian Bioscience, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
